SAb Biotherapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Florida, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
777 W 41st St Ste 401, Miami Beach, Flor...Phone Number
(305) 845-2813Website
sab.bioRevenue
-Stock Symbol
SABSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SAb Biotherapeutics
SAB BIO is classified as a clinical-stage biotechnology company engaged in the research and development of human polyclonal antibody therapeutics. The company develops innovative immunotherapies for autoimmune disorders, infectious diseases, and other immune-related conditions using proprietary biotechnology platforms.Explore more
SAb Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SAb Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
SAb Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once SAb Biotherapeutics has new funding data
Check out if SAb Biotherapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at SAb Biotherapeutics
Product Launch: Get notified when SAb Biotherapeutics launches new products
Earning: See what the market has to say on SAb Biotherapeutics recently announced quarterly report
Check if SAb Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if SAb Biotherapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at SAb Biotherapeutics
Find 2 more new buyers
Compare Similar Companies to SAb Biotherapeutics
Compare insights from companies similar to SAb Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SAb Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SAb Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SAb Biotherapeutics.
SAb Biotherapeutics financials insights
Gather financial insights about SAb Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Other Financing Round
$3M
2016
Grant
$1.4M
2018
Series A
$22M
2020
Debt
$350K
Series B
$36.4M
2025
Stock/Share Issuance
$175M
SAb Biotherapeutics Tech Stack
A closer look at the technologies used by SAb Biotherapeutics
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Person-Based
Medical Research, Pharmaceuticals
SAb Biotherapeutics News & Media
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its second quarter 2026 financial results will be issued on the morning of Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support ofBarclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside. On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle’s projections, the stock currently offers a […]SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SAb Biotherapeutics
Sign Up For FreeTo access detailed company insights
SAB BIO is classified as a clinical-stage biotechnology company engaged in the research and development of human polyclonal antibody therapeutics. The company develops innovative immunotherapies for autoimmune disorders, infectious diseases, and other immune-related conditions using proprietary biotechnology platforms.... Read More
